<p>Supplementary Table 5 | Incidence of neurotoxicity following taxane rechallenge Study Regimen type Neurotoxicity 1. Seidman Paclitaxel (120–140 mg/m2 over 96 h) Neurosensory toxicity: grade 1–2: 42% (11/26 et al. (1996)1 patients); grade 3–4: 4% (1/26 patients) Taguchi et al. Paclitaxel (80 mg/m2) Neuropathy: grade 1–2: 37% (17/46 patients); (2004)2 grade 3–4: 2.2% (1/46 patients) Yonemori Paclitaxel (80 mg/m2) Neurosensory toxicity: grade 1–2: 62.2% et al. (2005)3 Blum et al. Albumin-bound paclitaxel (100 mg/m2) Sensory neuropathy: grade 2: 18% (17/106 (2007)4 patients); grade 3: 9% (8/106 patients) Albumin-bound paclitaxel (125 mg/m2) Sensory neuropathy: grade 2: 24% (32/75 patients); grade 3: 14% (19/75 patients) Valero et al. Docetaxel (100 mg/m2) Neurosensory toxicity: total: 73.9% (34/46 (1998)5 patients); grade 3: 6.5% (3/46 patients) Neuromotor: total: 13.0% (6/46 patients); grade 3: 0% Lin et al. Docetaxel (75 mg/m2) Neurotoxicity: grade 1–2: 63% (15/24 (2000)6 patients); grade 2–4: 4% (1/24 patients) Seidman, A. D. et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 14, 1877– 1884 (1996). 2. Taguchi, T. et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J. 10, 509–513 (2004). 3. Yonemori, K. et al. Efficacy of weekly paclitaxel for docetaxel-resistant metastatic breast cancer. Breast Cancer Res. Treat. 89, 237–241 (2005). 4. Blum, J. L. et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer 7, 850–856 (2007). 5. Valero, V. et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 16, 3362–3368 (1998). 6. Lin, Y. C., Chang, H. K., Wang, C. H., Chen, J. S. & Liaw, C. C. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross resistance between paclitaxel and docetaxel. Anticancer Drugs 11, 617–621 (2000).</p><p>1</p>